Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system

Nikolaus R. McFarland, Jeng Shin Lee, Bradley T. Hyman, Pamela J McLean

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Enhanced delivery and expression of genes in specific neuronal systems is critical for the development of genetic models of neurodegenerative disease and potential gene therapy. Recent discovery of new recombinant adeno-associated viral (rAAV) capsid serotypes has resulted in improved transduction efficiency, but expression levels, spread of transgene, and potential toxicity can differ depending on brain region and among species. We compared the transduction efficiency of titer-matched rAAV 2/1, 2/5, and 2/8 to the commonly used rAAV2/2 in the rat nigrostriatal system via expression of the reporter transgene, enhanced green fluorescent protein. Newer rAAV serotypes 2/1, 2/5, and 2/8 demonstrated marked increase in transduction and spread of enhanced green fluorescent protein expression in dopaminergic nigrostriatal neurons and projections to the striatum and globus pallidus compared to rAAV2/2 at 2 weeks post-injection. The number of nigral cells transduced was greatest for rAAV2/1, but for serotypes 2/5 and 2/8 was still two- to threefold higher than that for 2/2. Enhanced transduction did not cause an increase in glial cell response or toxicity. New rAAV serotypes thus promise improved gene delivery to nigrostriatal system with the potential for better models and therapeutics for Parkinson disease and other neurodegenerative disorders.

Original languageEnglish (US)
Pages (from-to)838-845
Number of pages8
JournalJournal of Neurochemistry
Volume109
Issue number3
DOIs
StatePublished - May 2009
Externally publishedYes

Fingerprint

Toxicity
Rats
Genes
Neurodegenerative diseases
Gene therapy
Transgenes
Neurodegenerative Diseases
Neurons
Brain
Globus Pallidus
Capsid
Dopaminergic Neurons
Genetic Models
Substantia Nigra
Neuroglia
Genetic Therapy
Parkinson Disease
Cell Count
Gene Expression
Injections

Keywords

  • Adeno-associated virus
  • Gene therapy
  • Parkinson disease
  • Striatum
  • Substantia nigra
  • Transduction

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. / McFarland, Nikolaus R.; Lee, Jeng Shin; Hyman, Bradley T.; McLean, Pamela J.

In: Journal of Neurochemistry, Vol. 109, No. 3, 05.2009, p. 838-845.

Research output: Contribution to journalArticle

McFarland, Nikolaus R. ; Lee, Jeng Shin ; Hyman, Bradley T. ; McLean, Pamela J. / Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. In: Journal of Neurochemistry. 2009 ; Vol. 109, No. 3. pp. 838-845.
@article{c874efe9fb564f9681a86fcfaece4d4f,
title = "Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system",
abstract = "Enhanced delivery and expression of genes in specific neuronal systems is critical for the development of genetic models of neurodegenerative disease and potential gene therapy. Recent discovery of new recombinant adeno-associated viral (rAAV) capsid serotypes has resulted in improved transduction efficiency, but expression levels, spread of transgene, and potential toxicity can differ depending on brain region and among species. We compared the transduction efficiency of titer-matched rAAV 2/1, 2/5, and 2/8 to the commonly used rAAV2/2 in the rat nigrostriatal system via expression of the reporter transgene, enhanced green fluorescent protein. Newer rAAV serotypes 2/1, 2/5, and 2/8 demonstrated marked increase in transduction and spread of enhanced green fluorescent protein expression in dopaminergic nigrostriatal neurons and projections to the striatum and globus pallidus compared to rAAV2/2 at 2 weeks post-injection. The number of nigral cells transduced was greatest for rAAV2/1, but for serotypes 2/5 and 2/8 was still two- to threefold higher than that for 2/2. Enhanced transduction did not cause an increase in glial cell response or toxicity. New rAAV serotypes thus promise improved gene delivery to nigrostriatal system with the potential for better models and therapeutics for Parkinson disease and other neurodegenerative disorders.",
keywords = "Adeno-associated virus, Gene therapy, Parkinson disease, Striatum, Substantia nigra, Transduction",
author = "McFarland, {Nikolaus R.} and Lee, {Jeng Shin} and Hyman, {Bradley T.} and McLean, {Pamela J}",
year = "2009",
month = "5",
doi = "10.1111/j.1471-4159.2009.06010.x",
language = "English (US)",
volume = "109",
pages = "838--845",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system

AU - McFarland, Nikolaus R.

AU - Lee, Jeng Shin

AU - Hyman, Bradley T.

AU - McLean, Pamela J

PY - 2009/5

Y1 - 2009/5

N2 - Enhanced delivery and expression of genes in specific neuronal systems is critical for the development of genetic models of neurodegenerative disease and potential gene therapy. Recent discovery of new recombinant adeno-associated viral (rAAV) capsid serotypes has resulted in improved transduction efficiency, but expression levels, spread of transgene, and potential toxicity can differ depending on brain region and among species. We compared the transduction efficiency of titer-matched rAAV 2/1, 2/5, and 2/8 to the commonly used rAAV2/2 in the rat nigrostriatal system via expression of the reporter transgene, enhanced green fluorescent protein. Newer rAAV serotypes 2/1, 2/5, and 2/8 demonstrated marked increase in transduction and spread of enhanced green fluorescent protein expression in dopaminergic nigrostriatal neurons and projections to the striatum and globus pallidus compared to rAAV2/2 at 2 weeks post-injection. The number of nigral cells transduced was greatest for rAAV2/1, but for serotypes 2/5 and 2/8 was still two- to threefold higher than that for 2/2. Enhanced transduction did not cause an increase in glial cell response or toxicity. New rAAV serotypes thus promise improved gene delivery to nigrostriatal system with the potential for better models and therapeutics for Parkinson disease and other neurodegenerative disorders.

AB - Enhanced delivery and expression of genes in specific neuronal systems is critical for the development of genetic models of neurodegenerative disease and potential gene therapy. Recent discovery of new recombinant adeno-associated viral (rAAV) capsid serotypes has resulted in improved transduction efficiency, but expression levels, spread of transgene, and potential toxicity can differ depending on brain region and among species. We compared the transduction efficiency of titer-matched rAAV 2/1, 2/5, and 2/8 to the commonly used rAAV2/2 in the rat nigrostriatal system via expression of the reporter transgene, enhanced green fluorescent protein. Newer rAAV serotypes 2/1, 2/5, and 2/8 demonstrated marked increase in transduction and spread of enhanced green fluorescent protein expression in dopaminergic nigrostriatal neurons and projections to the striatum and globus pallidus compared to rAAV2/2 at 2 weeks post-injection. The number of nigral cells transduced was greatest for rAAV2/1, but for serotypes 2/5 and 2/8 was still two- to threefold higher than that for 2/2. Enhanced transduction did not cause an increase in glial cell response or toxicity. New rAAV serotypes thus promise improved gene delivery to nigrostriatal system with the potential for better models and therapeutics for Parkinson disease and other neurodegenerative disorders.

KW - Adeno-associated virus

KW - Gene therapy

KW - Parkinson disease

KW - Striatum

KW - Substantia nigra

KW - Transduction

UR - http://www.scopus.com/inward/record.url?scp=64149106830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64149106830&partnerID=8YFLogxK

U2 - 10.1111/j.1471-4159.2009.06010.x

DO - 10.1111/j.1471-4159.2009.06010.x

M3 - Article

C2 - 19250335

AN - SCOPUS:64149106830

VL - 109

SP - 838

EP - 845

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 3

ER -